GSK PLC-SPON ADR (GSK) Institutional Ownership Changes & 13F Activity

GSK PLC-SPON ADR (GSK) institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC 13F filings (Q1 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions among tracked filers. Notable filers include Dodge & Cox Stock Fund, Renaissance Technologies LLC, Causeway Capital Management, Kahn Brothers Group, and Hillman Value Fund.

Portfolio quarterNameTypeQuantityRemainingReported stock balance
Q1 2024Hillman Value FundBuy100233,486$10,009,545
Q4 2023Dodge & Cox Stock FundSell-254,39069,026,793$2,558,132,949
Q4 2023Causeway Capital ManagementBuy230,694795,441$29,479,046
Q4 2023Renaissance Technologies LLCSell-146,8002,765,193$102,478
Q4 2023Ariel Appreciation FundSell-86,10555,392$2,052,828
Q4 2023Tweedy, Browne Co All Funds (US)Sell-5,594124,400$4,610,264
Q4 2023Sequoia Financial AdvisorsBuy5,48521,177$784,912
Q4 2023Hillman Value FundBuy522233,386$8,649,285
Q3 2023Dodge & Cox Stock FundSell-330,08569,281,183$2,511,442,884
Q3 2023Causeway Capital ManagementBuy165,317564,747$20,472,082
Q3 2023Renaissance Technologies LLCSell-110,1412,911,993$105,560
Q3 2023Ariel Appreciation FundSell-30,180141,497$5,129,266
Q3 2023Tweedy, Browne Co All Funds (US)Sell-4,520129,994$4,712,282
Q3 2023Hillman Value FundSell-1,817232,864$8,441,320
Q3 2023Sequoia Financial AdvisorsBuy1,58515,692$568,930
Q2 2023Renaissance Technologies LLCSell-1,207,3173,022,134$107,709
Q2 2023Dodge & Cox Stock FundSell-95,80069,611,268$2,480,945,592
Q2 2023Causeway Capital ManagementBuy80,270399,430$14,235,678
Q2 2023Ariel Appreciation FundSell-13,691171,677$6,118,568
Q2 2023Hillman Value FundSell-2,735234,681$8,364,031
Q2 2023Tweedy, Browne Co All Funds (US)Sell-861134,514$4,794
Q2 2023Sequoia Financial AdvisorsBuy36314,107$502,774
Q1 2023Dodge & Cox Stock FundBuy4,774,11669,707,068$2,480,177,479
Q1 2023Renaissance Technologies LLCSell-2,107,7004,229,451$150,484
Q1 2023Causeway Capital ManagementBuy82,127319,160$11,355,718
Q1 2023First Eagle U.S. ValueSell-59,4573$101
Q1 2023Tweedy, Browne Co All Funds (US)Sell-3,952135,375$4,817
Q1 2023Sequoia Financial AdvisorsBuy2,82413,744$489,012
Q1 2023Hillman Value FundSell-463237,416$8,447,261
Q1 2023Ariel Appreciation FundBuy80185,368$6,595,393

Frequently asked questions about GSK activity

  • Which institutional owners are buying GSK?

    Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.

  • What does "buy" mean in GSK activity?

    "Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).

  • Is institutional interest in GSK increasing?

    Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.

Related GSK insights